Within the 217 records in this dataset, a single assignee leads with 78 records, more than four times the fifth-place count of 17. The top five assignees combined account for 173 records, 79.7% of the total, so the field is heavily concentrated at the top with a long tail of smaller filers behind it. Anyone entering this space should expect the leading assignee's portfolio to touch most core hydrolysis and taste-masking methods.

The largest technology classes in the dataset are foods and non-alcoholic beverages (A23L, 75.1% of records) and proteins and food peptides (A23J, 56.2%), which together point to enzymatic protein hydrolysis and the resulting peptide profile as the central technical problem. A recurring secondary problem, illustrated by the representative filing in this dataset, is that hydrolysis reduces allergenicity but produces bitter peptides that require separate taste-masking or pH-adjustment methods. Medicinal-preparation claims (A61K, 47.0%) also appear often, showing many filings are framed with a therapeutic or clinical angle rather than purely as food processing.

Filing activity peaked so far in 2019 at 33 records, and growth cannot be reliably computed for the most recent years because publication typically lags filing by roughly 18 months. That means 2024-2026 figures in any dataset will look artificially low and should not be read as a genuine slowdown. A fair read of momentum requires waiting for those later years to finish publishing before drawing conclusions.

The technology composition shows heavier claim density in core hydrolysis and food-processing classes (A23L, A23J) than in areas like clinical tolerance data used to support labelling claims or animal-feed adaptations of hydrolysate methods (A23K, 18.4% of records). Enzyme selection specifically targeted at reducing residual allergenicity, rather than general hydrolysis, also shows comparatively thinner coverage relative to the core claim territory. These narrower, clinically-grounded angles are the more realistic places to stake a defensible first claim given how concentrated the core methods already are.

Among the receiving offices captured in this dataset, Europe (EPO) leads with 26 filings, followed by the United States with 23 and Australia with 21; WIPO (PCT) filings account for 14. This spread suggests applicants in this field are pursuing multi-jurisdiction protection through both regional and international routes rather than concentrating filings in a single office. Counsel evaluating freedom to operate should check coverage across at least these leading offices rather than assuming a single-jurisdiction search is sufficient.